secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK:        0001048477
Form:       8-K
Filed at:   2022-09-12T23:59:59+00:00
Accession:  0001193125-22-242460
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

BioMarin reports phase 3 BMN 270 patient diagnosed with leukemia; initial tests find no link to therapy
--------------------------------------------------------------------------------

- BMN 270 phase 3 participant diagnosed with B-ALL; 85% of leukemic cells had Ph-like translocation.
- BMN 270 vector DNA in leukemic cells was negligible (<1 copy per 500 cells), suggesting no clonal expansion.
- No trial hold; all BMN 270 studies continue enrollment; DSMB agreed no modification needed.
- BioMarin remains on track to resubmit BMN 270 BLA to FDA by end of September 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1048477/000119312522242460/0001193125-22-242460-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1048477/000119312522242460/d306559d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-242460

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer